Breaking News

Vetter Executive Joins iBIO board

Roth to offer expertise in aseptic manufacturing

Related CONTENT

Kristin Brooks01.22.14

Claudia Roth, Ph.D., president of Vetter Development Services USA, Inc., has been appointed to the board of directors of the Illinois Biotechnology Industry Organization (iBIO), a life sciences industry association. Dr. Roth heads Vetter's clinical manufacturing facility in Chicago, IL.

Dr. Roth will offer her leadership and expertise in aseptic manufacturing to help iBIO promote and expand life sciences centers in Illinois and the surrounding Midwest.

Related Searches

Suggested For You

Vetio Animal Health

Vetio Animal Health

Innovative Manufacturing Technology for Aseptic Filling

Innovative Manufacturing Technology for Aseptic Filling

Aseptic Manufacturing Trends Roundtable

Aseptic Manufacturing Trends Roundtable

Newsmakers: Peter Soelkner

Newsmakers: Peter Soelkner

Vetter's Ravensburg Ops Underway

Vetter’s Skokie Site Launches New Clinical Syringe Filling Line

Vetter’s Skokie Site Launches New Clinical Syringe Filling Line

Vetter Data Processing Center Gains Certification

Vetter Data Processing Center Gains Certification

Developing a Lyophilized Drug Product? Don’t Forget the Diluent

Developing a Lyophilized Drug Product? Don’t Forget the Diluent

Vetter Expands US Footprint

Vetter Expands US Footprint

Vetter Development Service Chicago Completes On-Site Expansion Activities

Vetter Development Service Chicago Completes On-Site Expansion Activities

Vetter Makes Development Service Division Changes

Vetter Makes Development Service Division Changes

Presentation: Setting up a successful multi-product clinical fill & finish operation

Presentation: Setting up a successful multi-product clinical fill & finish operation

iBio, Caliber Select Cancer Target

iBio, Caliber Select Cancer Target

iBio Names Senior Management for Brazil Unit

iBio Names Senior Management for Brazil Unit

Related Breaking News

Breaking News | Drug Development | Industry News

Anixa Biosciences, MolGenie Find COVID Compounds Effective Against Omicron

Results of a genomic variant analysis indicate that the compounds in development should be effective against the Omicron variant.
12.07.21
Breaking News | Clinical Trials | Collaborations & Alliances | Drug Development

Ionis, AstraZeneca Partner to Develop and Commercialize Eplontersen

Will develop a global strategy for developing, manufacturing and commercializing eplontersen, an antisense medicine to treat transthyretin amyloidosis.
12.07.21
Breaking News | Drug Development

Emergence Therapeutics Closes €87 Million Series A Financing Round

Plans to advance its Nectin-4 antibody drug conjugate.
12.07.21
Breaking News

FourKites, Accenture Share Global Pharma Supply Chain Insights

Pharma executives cite supply chain visibility as critical solution to alleviating product loss and security concerns.
12.07.21
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News | Scale-up/Technology Transfer

BrainStorm, Catalent Complete Tech Transfer for NurOwn

Autologous cell therapy for the treatment of ALS and PMS will be manufactured at Catalent’s 32,000 sq.-ft. cell therapy manufacturing facility in Houston.
12.07.21
Breaking News | Drug Discovery

Metrion Biosciences Enhances Ion Channel Drug Discovery Service Capabilities

Appoints Dr. Gary Clark to lead the expanded services and cell biology capabilities.
12.07.21
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News

EMA Expands Authorization for Roche’s Actemra/RoActemra in COVID

An accelerated assessment by the EMA’s CHMP reviewed results from four studies of Actemra/RoActemra in over 5,500 patients with severe or critical COVID-19.
12.07.21
Breaking News | Industry News

Roquette Invests $25M in U.S. Pharmaceutical Innovation Center

New 23,000 sq.-ft. facility will house an Applied Sciences facility for the research of excipients for oral dosage forms, drug delivery systems, and APIs.
12.07.21
Breaking News | Trials & Filings

Lilly's Bamlanivimab and Etesevimab Gain EUA for Pediatric Use

Expanded authorization based on safety and efficacy in phase 2/3 BLAZE-1 trial in mild to moderate COVID-19 and high risk patients.
12.06.21
Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery | Information Technology

Recursion, Bayer Expand Strategic Fibrosis Alliance

To leverage Recursion's inferential search capabilities based on maps of human cellular biology to accelerate work in fibrotic disease.
12.06.21
Breaking News | Promotions & Moves

Biohaven Appoints Chairman and CFO

Vlad Coric to serve as Chairman and Matthew Buten as Chief Financial Officer.
12.06.21
Breaking News | Drug Development

Astellas Pharma and Dyno Therapeutics Sign Option and License Agreement

Will collaborate to develop next-gen AAV gene therapy vectors for skeletal and cardiac muscle.
12.02.21
Breaking News | Industry News | Vials

SCHOTT Continues to Expand U.S. Presence

Setting a strategic portfolio in the U.S. aims to capitalize on the world’s largest economy and capacity for innovation.
12.02.21
Breaking News | Clinical Trials

Sotio Biotech Secures Funding to Expand & Advance Its Clinical Pipeline

Proceeds will be used to conduct two phase 2 studies with SOT101, including a checkpoint inhibitor combination trial.
12.02.21
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News

FUJIFILM Diosynth Biotechnologies Invests £400M in UK Bio-Mfg. Site

Expansion will more than double the site’s development and manufacturing footprint and is expected to create as many as 350 highly-skilled jobs in Teesside.
12.02.21